Manuela T. Mancini-Selores

Bologna, 94013, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Journal: International journal of molecular sciences

Published: July 30, 2024

SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.

SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.

Journal: Clinical and translational medicine

Published: June 10, 2024

Comparison of classification methods performance for defining the best reuse of waste wood material using NIR spectroscopy.

Comparison of classification methods performance for defining the best reuse of waste wood material using NIR spectroscopy.

Journal: Waste management (New York, N.Y.)

Published: November 22, 2023

Application of Near Infrared Spectroscopy for the Rapid Assessment of Nutritional Quality of Different Strawberry Cultivars.

Application of Near Infrared Spectroscopy for the Rapid Assessment of Nutritional Quality of Different Strawberry Cultivars.

Journal: Foods (Basel, Switzerland)

Published: July 25, 2023

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.

Journal: Cells

Published: May 25, 2023

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.

Journal: Biomarker research

Published: December 15, 2022

Classification of waste wood categories according to the best reuse using FT-NIR spectroscopy and chemometrics.

Classification of waste wood categories according to the best reuse using FT-NIR spectroscopy and chemometrics.

Journal: Analytica chimica acta

Published: November 10, 2022

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.

Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.

Journal: Leukemia

Published: March 24, 2022

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.

Journal: Frontiers in oncology

Published: March 21, 2022

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.

Journal: Cancers

Published: December 13, 2021

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.

Journal: OncoTargets and therapy

Published: November 10, 2021

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.

Journal: Frontiers in oncology

Published: June 21, 2021

Showing 1-12 of 61

Last Updated: 09/26/2026